RGLS Regulus Therapeutics Inc Recent Headline News
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 320.75 (-2.72), ALNY: 95.84 (+2.93), ISIS: 44.59 (-0.66), OGXI: 2.18 (-0.02), TEVA: 57.70 (-1.02), RGLS: 22.08 (+2.42), GSK: 44.91 (+0.16), SNY: 45.69 (-0.17)
Regulus to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2014 at 10:30 a.m. MST. The conference is being held at the Arizona Biltmore in Phoenix, AZ.
RGLS: 22.08 (+2.42)
Insider Trading Alert - CBG, RGLS And WAB Traded By Insiders
at The Street - Thu Nov 06, 10:45AM CST
Stocks with insider trader activity include CBG, RGLS and WAB
CBG: 31.88 (+0.08), RGLS: 22.08 (+2.42), WAB: 89.27 (+0.99)
Regulus Therapeutics (RGLS) is in Overbought Territory: What's Next?